The patent covers a method for improving sexual function by activating serotonin or dopamine neurotransmission, or a combination of both. The compound is initially being developed for the treatment of erectile dysfunction (ED).
Zoraxel simultaneously enhances the levels of both serotonin and dopamine neurotransmitters in the brain, both of which play key roles in sexual motivation, erection and release. It is being developed as the first sexual dysfunction drug to effect all three phases of sexual activity.
Chang Ahn, chairman and CEO, said: “This latest patent coverage for Zoraxel significantly strengthens our patent estate. When added to the four CNS-related US patents and two anticancer patents already secured, this represents another key milestone for the company as we move forward with the clinical development for this promising new drug.”